USRE38102EExpiredUtility
Use of a pyridazinone derivative
Est. expiryJun 19, 2018(expired)· nominal 20-yr term from priority
A61P 9/06A61P 9/04A61P 43/00A61K 31/50A61P 9/00
71
PatentIndex Score
5
Cited by
22
References
8
Claims
Abstract
A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure comprises administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A method for the treatment of neurohumoral imbalance caused by alterations of cardiac function to prevent the development of heart failure by administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]acetamide to a mammal in need of such treatment.
2. The method according to claim 1 , wherein said compound is administered to a human in oral doses ranging from 0.1 to 500 mg per day.
3. The method according to claim 2 , wherein said compound is administered in oral doses ranging from 0.5 to 10 mg per day.
4. A method of increasing calcium sensitivity of troponin, which method comprises administering an effective amount of (R)-N-[4-(1,4,5,6-tetrahyro-4-methyl-6-oxo-3pyridazinyl)phenyl]acetamide to a mammal.
5. The method acording to claim 4 , wherein said compound is administered to a human in oral doses ranging from 0.1 to 500 mg per day.
6. The method according to claim 5 , wherein said compound is administered in oral doses ranging from 0.5 to 10 mg per day.
7. A method of increasing calcium sensitivity of contractile proteins of cardiac muscle in a mammal, which method comprises administering an effective amount of ( R )- N -[ 4 -( 1 , 4 , 5 , 6 - tetrahydro - 4 - methyl - 6 - oxo - 3 - pyridazinyl ) phenyl]acetamide to the mammal.
8. A method for reducing the need for neurohumoral activation in a patient, which comprises administering to the patient an effective amount of ( R )- N -[ 4 -( 1 , 4 , 5 , 6 - tetrahydro - 4 - methyl - 6 - oxo - 3 - pyridazinyl ) phenyl]acetamide.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.